Medicine Recommendations

Maintenance in schizophrenia and other psychoses

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Asthma in adults aged 17 and over

Asthma in children aged 12 to 16

COPD

Refer to LSCMMG COPD Guidelines

Depressive illness, obsessive compulsive disorder

The colour classification was determined as part of the collaborative work between LCFT and medicines management leads. Local pathways and patient safety were taken into consideration.

Emergency treatment of poisoning (Ethylene glycol and methanol)

Following a gastric bypass

Following an adjustable gastric band or sleeve gastrectomy

Following bariatric surgery performed privately

Treating refractory chronic immune thrombocytopenia - NICE TA835

NICE TA835 - Fostamatinib for treating refractory chronic immune thrombocytopenia

Fremanezumab for preventing migraine (NICE TA764)

NICE TA764 - Fremanezumab for preventing migraine

Migraine prophylaxis

Neuropathic pain (as per LSCMMG Guidelines)

Neuropathic pain

Restless Legs Syndrome (off-licence as per LSCMMG Guidelines)

Alzheimer's Dementia (NICE TA217)

NICE TA659 Galcanezumab for preventing migraine

Type 2 diabetes